Bromodeoxyuridine (BrdU), whether administered in a 30-hr pulse of 30 Mg/ml or continuously in low concentrations (1-3 ug/ml), significantly increased production of particles with the morphology of murine leukemia virus in a mouse melanoma (B16) Reversible suppression of tumorigenic potential of mouse melanoma cells grown in culture for long periods in medium containing low concentrations of the thymidine analog 5-bromodeoxyuridine (BrdU) has been demonstrated (1, 2). Morphology of these cells changed dramatically during growth in the presence of BrdU, although the growth rate remained essentially normal when the concentration was 1 jig/ml. These effects required DNA synthesis, and BrdU was incorporated into the DNA (1, 2). Further, mice injected with a clonally derived strain grown continuously in the presence of 
group-specific antigens 1 and 3 and for Gross cell-surface antigens) became positive. All BrdU-treated cells, regardless of drug concentration or length of treatment, in addition to showing loss of both pigment and of piled-up morphology, were suppressed in tumorigenicity compared with the control cells. These effects were all reversible. A significant percentage of mice injected with BrdU-treated cells were protected against subsequent tumor formation when challenged with malignant control cells. The degree of protection conferred on the mice correlated well with the number of virus particles counted in the injected cells. There was also good correlation between the amount of cell-associated virus and the degree of suppression of malignancy for cells treated continuously with 1 Mg of BrdU per ml, but not as good for cells treated for short periods with higher concentrations of BrdU.
Reversible suppression of tumorigenic potential of mouse melanoma cells grown in culture for long periods in medium containing low concentrations of the thymidine analog 5-bromodeoxyuridine (BrdU) has been demonstrated (1, 2) . Morphology of these cells changed dramatically during growth in the presence of BrdU, although the growth rate remained essentially normal when the concentration was 1 jig/ml. These effects required DNA synthesis, and BrdU was incorporated into the DNA (1, 2) . Further, mice injected with a clonally derived strain grown continuously in the presence of 1 ,gg of BrdU per ml developed a degree of immunity to subsequent challenge with the 100% malignant melanoma cells in direct proportion to the number of prior injections with the BrdU-treated cells. Four inoculations at weekly intervals immunized 90% of the mice (2) . We also observed large numbers of particles with the morphology of murine leukemia viruses in cells grown continuously in medium containing BrdU, as compared with untreated cells.
Recent reports indicated that a short pulse with high concentrations of BrdU (20-200 Mg/ml), or of other halogenated pyrimidines, can "induce" previously unexpressed virus in various mouse (3, 4) and rat (5) cells, including embryonic mouse cell lines. In view of this, a series of experiments was undertaken to determine whether similar treatment of the melanoma cell line would (a) produce reversible suppression of malignancy, (b) alter the morphology, as did longer periods of growth with 1-3 ,ug of BrdU per ml and, (c) "induce" virus production and release. When positive results were obtained in all three of these parameters with a short pulse, correlations were sought between the number of viruses associated with cells treated with BrdlT in various ways and for different lengths of time, and between suppression of malignancy and induction of immunogenicity.
MATERIALS AND METHODS
The pigmented clone B559 was derived (6, 7) from a melanoma (B16), which originated spontaneously in a C57BL/6 mouse (8 (Tables 1, 2 and refs. 1 and 2). Continuous growth in 1 jug of BrdU per ml gradually lowered tumorigenicity, but it was necessary to clone the cells to obtain strains of zero or very low tumorigenic potential, indicating that there was heterogeneity in the cell population grown with BrdU in the medium. Clones selected for lowest tumorigenicity began to produce more tumors after 7-8 subcultures and had to be recloned to derive new strains of equally low tumorigenic potential (Table 1) . For example, clones b and c of line 471 each produced a tumor in only 1 of 10 animals tested, whereas clone a produced tumors in 7 out of 10 mice (1). Clone c continued to be almost nontumorigenic until subculture 11, when it produced tumors in 5 out of 10 mice. On recloning, subelone cl was found to be highly tumorigenic, but subelone C3 was not tumorigenic up to the 8th passage, after which tumorigenicity began to increase ( A and type C) (15) were counted as described in Methods. Table 3 and Fig. 2 give the results of these studies and Fig.  3 shows a representative electron micrograph. Fig. 2 shows that the number of viruses in all BrdU-treated cells was significantly greater than in control cells. There are variations in the number of budding and extracellular viruses depending on mode and length of treatment.
When cells that were grown in 1 yg of BrdU per ml for different lengths of time (cloned and uncloned) were compared with each other and with control and reversed cells ( Fig. 2A  and B) , there was an inverse correlation between the number of virus particles and degree of tumorigenicity. This was less evident with other modes of treatment ( Fig. 2C and D) . Cells pulsed for 30 hr showed very few viruses after 5 days in RM and produced tumors in only 44%0 of the inoculated mice. When the same cells were then allowed to grow in 1 ug of BrdU/ml, the number of viruses increased and tumorigenicity decreased to zero. If the same pulsed cells grew in RM for a total of 41 days, virus counts increased to a lesser extent, but tumorigenicity returned to 100%. On the other hand, cells grown for 14 days in medium containing 3 Mg of BrdU/ml were completely nontumorigenic, but very few virus particles were observed. were completely reversed in normal medium to 100% tumorigenicity, the mean virus count per cell section was lower than that for any of the subcultures growing in BrdU. All reversed populations continued to release similar small numbers of virus particles (Fig. 2) .
A closer correlation exists between number of cell-associated viruses and degree of immunogenicity (Table 3 ). The greatest protection against challenge with 101 cells of the 100% tumorigenic parental line was offered by subclone c3471-8, which had the highest virus counts, while passages with lower virus counts offered less protection. Melanoma cells gave no protection when subtumorigenic numbers were injected 3 times, at weekly intervals, before challenge.
The ultrastructure of the observed particles resembled that of murine leukemia type C and enveloped A viruses (Fig. 3) .
Cells grown in medium with BrdU (c3471-15) and supernatant fluid were assayed by Dr. W. Rowe by the UV-XC method (10) . The results indicated the presence of a murine leukemia virus with a titer of 101.9 plaque-forming units per 0.1 ml of medium. No virus was discernible by this method in the control cells. c3471 cells were also strongly positive for MuLV gs-1, as well as gs-3 antigens, whereas the B559 cells were negative, as assayed by the indirect irnmunofluorescence technique by Dr. W. Hardy (12, 13) . Preliminary results in this laboratory indicate that the c3471 cells possess the Gross cell-surface antigen, which was not detected in the control cells.
DISCUSSION
When mouse melanoma cells are grown in a medium containing BrdU several changes occur. Malignancy and pigmentation are suppressed and cells no longer grow in piled-up colonies, but form "density-dependent" monolayers of flattened cells. All of these changes are reversible and apparently dependent on continued DNA synthesis (1, 2 Silagi, Weksler, and Newcomb show that cells grown for 14 days in medium with 3 jug of BrdU per ml that never form tumors in young adult mice form tumors in some immunosuppressed adults and in some neonates, indicating that increased antigenicity is one important factor in BrdU-induced suppression of tumorigenicity. Virus production is probably not the only factor leading to decreased tumorigenicity, as indicated by the poor correlation between number of viral particles and suppression of tumorigenicity in the experiments with higher concentrations of BrdU for relatively short periods. It is possible that these conditions are somewhat toxic, as reflected in lowered plating efficiency (2). Short periods of treatment also may not give cells enough time to become producers of large amounts of virus.
BrdU-treated cells, which had lost tumorigenicity and then regained it after growth in RM, had more virus than controls. This may reflect the fact that not every cell in this population reverses. It should be emphasized that in the most extensively studied clone, c3471, all passages growing in medium with BrdU that were studied by electron microscopy had higher counts than reversed cells.
The etiological role of the virus is completely unknown. Although the virus possesses serological and ultrastructural properties of MuLV, mice that were repeatedly injected with cells high in virus production did not develop leukemia, even when kept for 1 year (2). Some retained the ability to reject a challenge throughout this period. Preliminary studies with cell-free preparations of the BrdU-induced viruses indicate that they produce polykaryocytes in various mouse cell lines, unlike known MuLV strains.
Aaronson has described induction of focus-forming virus in nonproducer strains of murine sarcoma-transformed cells by treatment with BrdU, IdU, and IdC (5-iododeoxycytidine).
These induced viruses had the host range and serological properties of the endogenous murine leukemia helper viruses (17) . It is, therefore, of interest that the virus induced in the C57BL/6 melanoma cells was "B-tropic", growing better in BALB/c embryo cells than in NIH/Swiss embryo cells (11) . C57BL/6 mice belong to the same host group as do BALB/c. Since Gross cell-surface antigen is always found in cells producing wild-type MuLV, it is not surprising that preliminary results indicate that the melanoma cells in which virus was induced were positive for this antigen.
Our findings of decreased tumorigenicity and increased antigenicity in BrdU-treated cells parallel the findings by Stephenson and Aaronson (18) in producer murine sarcomatransformed cells as compared with nonproducer cells. Further, the presence of a virus in BrdU-treated cells that has the antigenic characteristics of an endemic MuLV, plus cytopathic characteristics unlike any described for known leukemia viruses, is consistent with the hypothesis that BrdU induced the endemic Gross strain of MuLV, which, in turn, acting as helper, rescued a possible murine melanoma virus. In any event, the increased antigenicity and decreased tumorigenicity of these cells after BrdU induction of virus may indicate new approaches to human tumor therapy.
